Clinical Trials Directory

Trials / Completed

CompletedNCT05564286

Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

Fosaprepitant Combined With Tropisetron Plus Dexamethasone in Preventing Nausea and Emesis During Fractionated Radiotherapy With Weekly Cisplatin Chemotherapy in Cervical Cancer and Nasopharyngeal Cancer

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
116 (actual)
Sponsor
Shantou University Medical College · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The study is to evaluate the antiemetic effect of adding fosaprepitant to biplet regimen of tropisetron and dexamethasone for patients with cervical cancer or nasopharyngeal cancer treated with radiotherapy and concomitant weekly cisplatin chemotherapy in a south Chinese cohort.

Detailed description

The study was designed as a prospective,randomized, single-blind control clinical trial aiming to assess the efficacy and safety of fosaprepitant combined with tropisetron and dexamethasone in preventing nausea and vomiting during 5 weeks of fractionated radiotherapy and concomitant weekly low-dose cisplatin chemotherapy in patients with cervical cancer or nasopharyngeal cancer.

Conditions

Interventions

TypeNameDescription
DRUGFosaprepitantIn fosaprepitant group, patients would receive fosaprepitant combined with tropisetron plus dexamethasone to prevent chemoradiotherapy-induced nausea and vomitting while the control group would only be given tropisetron and dexamethasone .
DRUGtropisetronAll patients received tropisetron 5mg on day 1.
DRUGDexamethasone.All patients received dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.

Timeline

Start date
2021-07-01
Primary completion
2023-07-31
Completion
2023-08-30
First posted
2022-10-03
Last updated
2024-02-06

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05564286. Inclusion in this directory is not an endorsement.